priority meds tirzepatide tirzepatide: complete guide and honest review Tirzepatide for Weight Loss |

FDA does not evaluate compounded products for safety, effectiveness, or quality

Future GLP-2 trials in IBD should stratify patients by disease phenotype (mucosal UC, inflammatory CD, stricturing CD) and incorporate serial cross-sectional imaging to monitor for stricture progression, given the mechanistic link between GLP-2R signaling through subepithelial myofibroblasts and intestinal fibrogenesis

The FDA label for Wegovy reports nausea in approximately 44% of patients, while Ozempic has lower rates (around 15-20%)

If 10 mg produces excellent efficacy but borderline intolerable nausea, try 7.5 mg for 6 to 8 weeks to assess whether efficacy remains adequate with improved tolerability